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Abstract
Summary This study investigated the effects of a single
administration of teriparatide on bone turnover markers
in postmenopausal women. Teriparatide caused a tran-
sient increase in bone resorption and inhibition of bone
formation followed by a subsequent increase in bone
formation and a decrease in resorption that lasted at
least 1 week.
Introduction This study aims to investigate the effects of
a single subcutaneous administration of teriparatide on
bone turnover markers to elucidate why once weekly
intermittent administration of teriparatide is effective on
osteoporosis.
Methods Pharmacokinetics and calcium metabolism and
bone turnover parameters were measured in 30 postmeno-
pausal women after two doses of teriparatide (28.2 or
56.5 μg injection) or placebo in a randomized, double-
blind, placebo-controlled study.
Results Teriparatide plasma concentration increased in a
dose-dependent manner, and the maximum concentration
was achieved 1 h after injection. Serum levels of calcium
and phosphorus were transiently increased and decreased
after teriparatide injection, respectively. Calcium metabo-
lism returned to baseline levels 24 h later. Two days after
injection, the serum level of 1,25-dihydroxy vitamin D was
increased by ~80 % from baseline for both doses of teripara-
tide. Serum levels of osteocalcin and procollagen type I N-
terminal propeptide decreased during the first 24 h followed
by a ~10 % increase for 14 days. The serum level of cross-
linked N-telopeptide (NTX) of type I collagen increased
during the first 24 h followed by a 10 to 12 % dose-
dependent suppression from baseline for 14 days. Urinary
cross-linked C-telopeptide of type I collagen changes oc-
curred in the same direction as serum NTX, but not dose
dependently.
Conclusion A single administration of teriparatide caused
an immediate, transient increase in bone resorption and
inhibited bone formation followed by an increase in bone
formation and decrease in resorption for ≥1 week. These
findings may provide proof for the effect of a once-weekly
regimen of teriparatide on bone turnover.
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Introduction
Teriparatide is the synthetic form of human parathyroid
hormone (PTH) 1-34 and has been widely used for the
treatment of osteoporosis with high risk of fracture as daily
[1–3] and weekly subcutaneous injections [4]. It has been
shown that continuous and intermittent administrations of
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teriparatide have different metabolic effects on bone. Con-
tinuous administration of PTH or teriparatide induced an
increase in bone resorption and a decrease in bone strength,
which resembles the pathophysiology of primary hyperpara-
thyroidism [5, 6]. Intermittent administration of teriparatide
induced large increases in bone formation followed by in-
creased bone resorption. The early increase in bone forma-
tion markers [procollagen type I N-terminal propeptide
(P1NP) or proco1lagen type I C-terminal propeptide
(P1CP)] after daily PTH or teriparatide injection has been
reported to associate with increases in spine or hip bone
mineral density (BMD) after treatment for 1 or 1.5 years [7,
8]. Therefore, early increases in bone formation markers
seem to be important for increased BMD after PTH or
teriparatide treatments. Although the differences in the
changes between bone resorption and formation continued
at least for 1 year, measurements in subsequent years
showed that these two metabolic processes were equally
stimulated [9]. Femoral neck BMD was increased by 3 to
4 % during a median of 19-month treatment with daily
teriparatide [2]. The increase was sustained in subjects re-
ceiving bisphosphonate after cessation of teriparatide and
rapidly decreased in subjects who received no subsequent
treatment for osteoporosis [10]. It is possible that the rapid
decrease in BMD once drug treatment was stopped may be
due to a predisposed increase in bone resorption. Over a
decade ago, Fujita et al. [11] reported that weekly adminis-
tration of teriparatide for 48 weeks increased lumbar BMD
by 0.6, 3.6, and 8.1 % with injection doses of 14.1, 28.2, and
56.5 μg, respectively. The maximum teriparatide dose
(56.5 μg injection) in a weekly injection was approximately
three times that of a daily administration of teriparatide
(20 μg injection). However, the total amount per week of
teriparatide in the daily injection schedule was ~2.5 times
higher than the weekly injection. Therefore, neither the dose
of each injection nor the total amount of dose received in the
weekly regimen is likely to explain the effects on BMD and
anti-fracture efficacy. In this context, we have attempted to
investigate the effects of a single injection of teriparatide on
bone turnover markers, calcium metabolism, pharmacoki-
netics (PK), and safety in postmenopausal women.
Methods
Study subjects
This was a single-center, randomized, double-blind,
placebo-controlled study. Postmenopausal Japanese women
between the ages of 60 and 79 years were eligible. The
inclusion criteria included postmenopausal women without
concomitant allergic diathesis, secondary osteoporosis, past
histories of extensive abdominal surgery, calcium
abnormalities, drug use which may affect bone metabolism,
or bone fractures within 12 weeks prior to the study.
Study drug
Teriparatide and the placebo, both of which were identical in
appearance, were supplied by Asahi Kasei Pharma
Corporation.
Study design
Eligible women were randomized before receiving a single
subcutaneous injection of placebo or teriparatide (28.2 or
56.5 μg). On the first day of administration (day 1), baseline
(0 h) examinations were performed at 0800 h. Teriparatide
or placebo was administered immediately after collection of
baseline blood and urine samples. Blood samples were
collected at 15, 30, 45, 60, 90, 120, 180, 240, 360, and
720 min after the injection. Urine samples were collected
120, 240, 360, and 720 min after the injection on day 1.
Subsequent blood and urine samples were collected at
0800 h on day 2 and in the morning on days 4, 6, 8, 11,
13, and 15.
Outcomes measures
PK, safety, and changes in calcium metabolism and bone
turnover markers were measured. Teriparatide acetate plas-
ma concentrations were measured at Daiichi Pure Chemicals
Co., Ltd. (Tokyo, Japan) using a rat PTH immunoradiomet-
ric assay (IRMA) kit (Immutopics, Inc., San Clemente, CA,
USA) with a range of 10 to 1,000 pg/mL. Measurement of
the markers of calcium metabolism [serum calcium (Ca),
inorganic phosphorus (P), and urinary excretion of Ca and
P] was performed at Mitsubishi Chemical Medience Co.
(Tokyo, Japan). Serum-corrected Ca was calculated by the
value of serum albumin [12]. Serum levels of intact PTH
were measured by an electrochemiluminescence immunoas-
say (Roche Diagnostics K.K., Tokyo, Japan). 1,25-Dihydroxy
vitamin D (1,25(OH)2D) was measured by a radio receptor
assay (TFB Inc., Tokyo, Japan), and 25-hydroxy vitamin D
(25(OH)D) was measured by a competitive protein-binding
assay (Mitsubishi Chemical Medience); the inter-assay coef-
ficient of variation (CV) was 11.3–13.2 and 3.7–9.9 %, re-
spectively. Serum levels of the bone turnover markers
osteocalcin and P1NP (both bone formation markers) were
measured by BGP-IRMA (Mitsubishi Chemical Medience,
Tokyo, Japan) and bone radioimmunoassay (Orion Diagnos-
tic, Espoo, Finland), respectively (inter-assay CV, 4.7–7.6 and
2.7–5.0 %, respectively). Serum cross-linked N-telopeptide of
type I collagen (NTX, Osteomark, Inverness Medical
Innovations Inc, Waltham, MA, USA) was measured by
ELISA, and urinary cross-linked C-telopeptide of type I
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collagen (CTX, Fujirebio Inc., Tokyo, Japan) was measured
by ELISA; both are bone resorption markers (inter-assay
CV, 6.9–11.1 and 2.4–9.0 %, respectively). All samples
from each participant were measured in a single batch.
Adverse events (AEs) occurring after teriparatide injec-
tion were collected.
Data and statistical analysis
Teriparatide plasma concentration was expressed as mean ±
SD. PK analyses were performed on women who received
active drug treatment by calculating the time course of
plasma drug concentration and several PK parameters
(Cmax, AUClast, AUCinf, Tmax, and T1/2). The calcium
metabolic markers and bone turnover markers were
expressed as the mean absolute values or mean percent
changes from baseline. The corresponding mean placebo
values were subtracted from the percent changes in order
to eliminate the diurnal and daily variations of the markers.
AEs (e.g., symptoms and abnormal changes in laboratory
values) were summarized after coding and classified accord-
ing to system organ class and preferred term using Med-
DRA/J (version 9.0). Statistical analysis using Dunnett’s test
was performed to examine the differences between the pla-
cebo and the two teriparatide groups.
Ethical considerations
The protocol of the present study was approved by the
Ethical Committee of the Medical Corporation Shinanokai
Shinanozaka Clinic. Written informed consent was




Thirty subjects (ten per group) were randomized into the
three treatment groups (placebo, 28.2 μg or 56.5 μg teri-
paratide). There were no dropouts during the study period.
The subject characteristics of the three groups were well
balanced at baseline, and there were no significant differ-
ences between the groups (Table 1). The serum level of 25
(OH)D in the 28.2 μg dose group seemed to be lower than
that in the other groups. However, none of the groups had a
level less than 10 ng/mL, suggesting that vitamin D defi-
ciency at baseline was not included.
Pharmacokinetics
The time course and the change in plasma teriparatide
acetate concentrations are shown in Fig. 1. The plasma
concentration of teriparatide increased in a dose-dependent
manner, and Cmax was achieved 1 h after the injection
(193.12±35.30 and 338.14±134.18 pg/mL and 28.2 and
56.5 μg groups, respectively). The remaining PK parameter
data were AUClast 25.84±3.18 and 49.91±11.33 ng/min/
mL, AUCinf 28.07±2.47 and 52.73±10.03 ng/min/mL,
Tmax 54.0±10.5 and 52.5±10.6 min, and T1/2 69.57±
13.04 and 77.69±35.22 min, in the 28.2 and 56.5 μg
groups, respectively.
Changes in calcium metabolism
Serum-corrected Ca increased rapidly and reached its peak
value 4 to 6 h after the injection, returning to baseline after
24 h (Fig. 2a). The maximum mean corrected serum Ca
Table 1 Characteristics of
subjects
BMI body mass index, Ca calci-
um, P inorganic phosphate, PTH
parathyroid hormone, P1NP
procollagen type I N-terminal
propeptide, NTX cross-linked
N-telopeptide of type I collagen,
CTX cross-linked C-telopeptide
of type I collagen





Age (years) 70.5±4.2 72.7±4.7 69.9±3.9
Height (cm) 152.26±5.36 151.34±5.11 152.14±4.43
Body weight (kg) 50.85±7.68 57.25±7.44 52.82±7.19
BMI (kg/m2) 21.93±3.03 25.08±3.76 22.94±3.88
Corrected serum Ca (mg/dL) 9.15±0.28 9.12±0.14 9.11±0.19
Serum P (mg/dL) 3.97±0.24 3.97±0.28 3.97±0.38
Serum intact PTH (pg/mL) 35.5±9.6 35.4±7.4 42.0±7.1
Serum 25(OH)D (ng/mL) 21.48±5.14 17.93±8.34 21.04±6.70
Serum 1,25(OH)2D (pg/mL) 58.6±16.5 54.8±16.7 57.8±13.3
Serum osteocalcin (ng/mL) 10.00±2.20 9.10±2.28 9.43±3.52
Serum PINP (ng/mL) 61.24±17.53 55.34±13.93 62.80±26.23
Serum NTX (nM BCE/L) 14.44±4.25 14.30±3.45 14.22±2.67
Urinary CTX (μg/mmol) 422.70±176.79 415.80±137.91 498.20±164.47
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level was 9.58 mg/dL in the 56.5 μg group, and the changes
were within the normal serum Ca range. None of the sam-
ples obtained after injection were outside the normal range
of serum Ca, and the changes were not dose-dependent.
Urinary Ca excretion was transiently decreased 4 h after
teriparatide administration and returned to the baseline level
within 24 h (Fig. 2b). Serum P decreased rapidly and
reached its lowest value 2 to 6 h after injection, and urinary
excretion of P increased rapidly after injection (Fig. 2c, d).
The serum levels of intact PTH were decreased during the
first 24 h after administration and returned to baseline at day
6 (Fig. 3a, b). Serum levels of 1,25(OH)2D after teriparatide
injection were increased for 2 days before returning to
baseline (Fig. 3c, d). There was no obvious dose-dependent
difference in Ca regulation changes after the teriparatide in-
jection. The median values at baseline and the distribution at
follow-up are indicated in Table 2.
Changes in bone formation markers
Percent change from baseline and percent changes sub-
tracted by the corresponding placebo values were calculated
for serum P1NP and osteocalcin. In the placebo group,
serum levels of P1NP and osteocalcin were increased after
injection followed by a gradual decrease to ~15 % below
baseline (Fig. 4a–d). These changes in bone formation
markers were considered to be due to circadian variations.
After adjustment for circadian variations, serum levels of
P1NP in the teriparatide-treated groups were decreased
shortly after the injection (−15 %) followed by a continuous
increase to ~15 % (Fig. 4d). The increase in P1NP was
maintained for 14 days after the injection. There were no
remarkable dose-related differences in P1NP changes. Se-
rum osteocalcin levels followed a similar trend including a
dose-dependent response. However, the late-phase increase
was not as obvious (+10 %).
Changes in bone resorption markers
The same technique to nullify the effects of circadian
rhythm was used to analyze serum NTX and urinary CTX
levels. Both serum NTX and urinary CTX levels were
increased transiently on day 1 followed by a 10 % decline
from baseline (Fig. 5a–d). This decline persisted during the
14 days of observation, and the urinary NTX levels de-
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Fig. 1 Plasma concentrations of teriparatide. Mean changes of teri-
paratide acetate (in picograms per liter) in plasma after a single sub-
cutaneous injection of teriparatide (filled circle 56.5 μg, filled triangle
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Fig. 2 Mean change of (a)
serum corrected calcium (in
milligrams per deciliter), (b)
urinary calcium (in milligrams
per gram Cr), (c) serum
phosphate (in milligrams per
deciliter), and (d) urinary
phosphate (in milligrams per
gram Cr) through 72 h after a
single subcutaneous injection of
teriparatide (filled circle
56.5 μg, filled triangle 28.2 μg)
or placebo (empty square).
Significant differences between
the teriparatide (number sign
56.5 μg, asterisk 28.2 μg) and
placebo groups (p<0.05)
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Safety outcomes
AEs occurred in 5 out of 10 subjects in the placebo group
and in all 10 subjects in each of the 28.2 and 56.5 μg
teriparatide groups (Table 3). AEs in two of the placebo
subjects and in all of the teriparatide subjects were classified
as adverse drug reactions (ADRs). ADRs observed in two or
more subjects treated with teriparatide were erythema at
injection site, somnolence, headache, and hot flashes. More
women in the 28.2 and 56.5 μg groups experienced ADRs
than their placebo-group counterparts, but most of these
ADRs were mild and resolved without intervention. More-
over, there were no significant differences between the 28.2
and 56.5 μg groups in the incidence or extent of ADRs.
There were also no significant changes in laboratory values
















Fig. 3 Mean percent change of
serum intact PTH (a, b) and
1,25(OH)2D (c, d) through
15 days after a single
subcutaneous injection of
teriparatide (filled circle
56.5 μg, filled triangle 28.2 μg)
or placebo (empty square).
Delta intact PTH (b) and Δ
1,25(OH)2D (d) were adjusted
by the corresponding placebo
value (formulation, each
measurement − mean placebo
value). Significant differences
between the teriparatide
(number sign 56.5 μg, asterisk
28.2 μg) and placebo groups
(p<0.05)
Table 2 Distribution of bone metabolic markers at baseline and at follow-up
Placebo group Teriparatide group (28.2 μg) Teriparatide group (56.5 μg)
Item Time Median Max Min Median Max Min Median Max Min
Intact-PTH (pg/mL) Baseline 33.5 53.0 24.0 34.5 50.0 28.0 42.5 52.0 32.0
2 to 24 h 43.0 75.0 22.0 34.5 66.0 17.0 35.0 65.0 18.0
4 to 15 days 46.5 81.0 27.0 45.5 64.0 25.0 49.0 109.0 26.0
1,25(OH)2D (pg/mL) Baseline 56.5 79.0 33.0 53.0 79.0 34.0 63.5 75.0 40.0
2 to 24 h 54.0 93.0 26.0 67.5 118.0 37.0 70.5 136.0 33.0
4 to 15 days 61.0 95.0 29.0 56.0 99.0 21.0 54.0 94.0 18.0
Serum osteocalcin (ng/mL) Baseline 9.6 13.4 7.3 8.8 12.5 5.4 9.2 15.8 4.2
2 to 24 h 8.6 13.6 5.5 7.6 12.7 4.6 7.4 16.7 3.2
4 to 15 days 8.6 12.4 4.8 8.1 12.2 4.6 7.9 17.9 4.3
Serum P1NP (ng/mL) Baseline 62.9 90.2 39.8 52.8 81.3 32.8 59.5 109.0 21.1
2 to 24 h 53.5 91.4 36.0 47.4 77.4 28.0 49.1 101.0 13.0
4 to 15 days 51.6 89.4 31.0 53.5 80.2 30.7 56.9 118.0 18.3
Serum NTX (nM BCE/L) Baseline 12.7 22.8 11.1 13.9 19.0 9.5 13.1 19.6 10.9
2 to 24 h 11.8 24.5 7.4 14.2 21.7 9.2 13.8 27.7 7.2
4 to 15 days 13.1 22.7 8.3 13.2 20.4 7.2 10.7 20.6 7.5
Urinary CTX (μg/mmol) Baseline 358.0 798.0 275.0 376.5 746.0 268.0 487.0 736.0 272.0
2 to 24 h 301.0 679.0 92.7 402.5 958.0 192.0 508.5 1190.0 238.0
4 to 15 days 374.0 722.0 202.0 351.0 655.0 106.0 351.0 972.0 142.0
PTH parathyroid hormone, P1NP procollagen type I N-terminal propeptide, NTX cross-linked N-telopeptide of type I collagen, CTX cross-linked
C-telopeptide of type I collagen
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Conclusions
The present study aimed to investigate the effects of a single
administration of teriparatide on calcium metabolism and
bone turnover markers for 2 weeks following administra-
tion. Long-term changes in bone turnover markers with
daily teriparatide administration have been well docu-
mented. Daily administration yields initial increases in bone
formation markers followed by increased bone resorption
markers [9]. This time difference in the responses of bone
turnover markers in daily teriparatide injection has been
referred to as an “anabolic window” [9]. The anabolic
window was presented as the reason that daily teriparatide
injection increased BMD. However, the late-phase increase
in bone resorption markers may rapidly decrease BMD after
teriparatide injections are stopped [13]. Although the daily
administration of teriparatide showed clinical benefits in-
cluding fracture prevention [2] and improvement of
patients’ quality of life [14], the daily self-administered
regimen is bothersome, especially for elderly patients. Fujita
et al. reported that once-weekly administration of teripara-
tide effectively increased BMD in postmenopausal osteopo-
rosis patients [11], and Nakamura et al. reported a
significant risk reduction for fracture [4]. However, there
had been no available data to demonstrate why once-weekly


















Fig. 4 Mean percent change of
serum P1NP (a, b) and
osteocalcin (c, d) through
15 days after a single
subcutaneous injection of
teriparatide (filled circle
56.5 μg, filled triangle 28.2 μg)
or placebo (empty square).
Delta serum P1NP (b) and Δ
serum osteocalcin (d) were






56.5 μg, asterisk 28.2 μg) and
placebo groups (p<0.05).














Fig. 5 Mean percent change of
serum NTX (a) and urinary
CTX (b) through 15 days after a
single injection of teriparatide
(filled circle 56.5 μg, filled
triangle 28.2 μg) and placebo
(empty square). Delta serum
NTX (b) and Δ urinary CTX
(d) were adjusted by the
corresponding placebo value
(formulation, each
measurement − placebo value).
Significant differences between
the teriparatide (number sign
56.5 μg, asterisk 28.2 μg) and
placebo groups (p<0.05). NTX
cross-linked N-telopeptide of
type I collagen, CTX cross-
linked C-telopeptide of type I
collagen
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PK analysis in the present study revealed that the teri-
paratide concentration peaked after 1 h and disappeared 6 h
after a single injection. To respond to the rapid rise in
teriparatide, serum calcium and urinary phosphate excretion
transiently increased. Increases in the serum level of 1,25
(OH)2D in response to teriparatide injection were observed.
These changes in calcium metabolism were within our ex-
pectation, and the findings indicated that a single injection
of teriparatide is biologically active in terms of calcium
metabolism. Cosman et al. reported that daily 20 μg teri-
paratide injections increased 1,25(OH)2D levels with a peak
effect occurring at 1 month and a persistent increase over
1 year [15]; a similar result was seen with weekly 56.5 μg
teriparatide therapy [11].
The response of bone turnover markers to a single ad-
ministration of teriparatide had not previously been investi-
gated. The present study indicated that a single
administration of teriparatide caused biphasic changes in
bone formation and resorption markers, namely, a rapid
increase in resorption markers and decrease in formation
markers for 1 or 2 days, followed by a sustained suppression
of resorption markers and stimulation of formation markers
for the subsequent 2 to 14 days. These bone marker changes
did not show dose dependency except for serum NTX, and
the magnitude of change in bone markers was smaller than
the changes seen with daily administration of teriparatide
[16]. The sustained late-phase response of bone turnover
markers in the present study may be one possible explana-
tion for the BMD increase seen with weekly administration
of teriparatide.
The present study includes several limitations. First, most
of the changes in calcium metabolic and bone turnover
markers after a single administration of teriparatide did not
show dose-related differences. However, the previous study
indicated that once-weekly administration of teriparatide
increased BMD in a dose-dependent manner [11]. There-
fore, the changes in calcium metabolic and bone turnover
markers may explain limited parts of the effect of teripara-
tide on bone. Furthermore, the magnitude of the changes in
the bone turnover markers was not enough to assess quan-
titatively; we were only able to assess them qualitatively.
Although the present study included the limitations men-
tioned above, the results indicate that a single administration
of teriparatide may have a sustained effect (14 days) in terms
of the changes in bone turnover markers. However, it is still
not clear as to whether or not repeated weekly administration







n (%) n (%) n (%)
Any adverse event 5 (50) 10 (100) 10 (100)
Nasopharyngitis 1 (10)
Decreased appetite 1 (10) 1 (10)
Headache 3 (30)
Somnolence 1 (10) 1 (10) 5 (50)
Conjunctival hyperemia 1 (10) 1 (10)
Eye pain 1 (10)
Positional vertigo 1 (10)
Palpitations 1 (10)
Hot flashes 3 (30) 1 (10)
Pharyngolaryngeal pain 1 (10)
Pharynx discomfort 1 (10)
Rhinorrhea 1 (10) 1 (10)
Nausea 1 (10)
Vomiting 1 (10) 1 (10)
Erythema 1 (10)
Muscle spasms 1 (10)
Musculoskeletal stiffness 1 (10)
Malaise 1 (10)
Injection site erythema 10 (100) 10 (100)
Increased blood potassium 2 (20) 1 (20)
Increased blood cholesterol 2 (20)
Decreased blood pressure 1 (10)
Contusion 1 (10)
Osteoporos Int (2013) 24:219–226 225
of teriparatide induces a more powerful reduction of bone
resorption and stimulation of bone formation. Therefore, fur-
ther research will be required.
We concluded that a single administration of teriparatide
caused an immediate, transient increase in bone resorption
and inhibition of bone formation followed by a subsequent
increase in bone formation and decrease in resorption for at
least 1 week. These findings may provide substantial proof
for the effect of a once-weekly regimen of teriparatide on
bone turnover.
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